The cost of delaying treatment in multiple sclerosis - What is lost is not regained

被引：35
|
作者：
Schwid, SR
Bever, CT
机构：
[1] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
[2] VAMHCS Baltimore, Neurol Serv, Baltimore, MD USA
[3] VAMHCS Baltimore, Res Serv, Baltimore, MD USA
[4] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA
来源：
NEUROLOGY | 2001年 / 56卷 / 12期
关键词：
D O I：
10.1212/WNL.56.12.1620
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1620 / 1620
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Multiple Sclerosis Treatment Approaches
    Hola, Martina
    Gajdos, Ondrej
    Kamensky, Vojtech
    Kubincova, Karolina
    ADVANCES IN DIGITAL HEALTH AND MEDICAL BIOENGINEERING, VOL 2, EHB-2023, 2024, 110 : 69 - 77
  • [22] COST-UTILITY ANALYSIS OF MULTIPLE SCLEROSIS TREATMENT IN THAILAND
    Chanatittarat, Chalakorn
    Chaikledkaew, Usa
    Prayoonwiwat, Naraporn
    Siritho, Sasitorn
    Pasogpakdee, Pakamas
    Apiwattanakul, Metha
    Riewpaiboon, Arthorn
    Thavorncharoensap, Montarat
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (06) : 584 - 592
  • [23] Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
    Wiendl, Heinz
    Meuth, Sven G.
    DRUGS, 2015, 75 (09) : 947 - 977
  • [24] DELAYING THE DIAGNOSIS - TRUTH-TELLING AND MULTIPLE-SCLEROSIS
    LEVINE, C
    HASTINGS CENTER REPORT, 1983, 13 (03) : 2 - 3
  • [25] Early-stage multiple sclerosis - What are the treatment options?
    Sorensen, PS
    DRUGS, 2004, 64 (18) : 2021 - 2029
  • [26] What treatment should be given for multiple sclerosis at the present time?
    Ramo-Tello, C
    León-Colombo, T
    REVISTA DE NEUROLOGIA, 2000, 30 (10) : 993 - 995
  • [27] MEDICINE TREATMENT COST OF MULTIPLE SCLEROSIS BEFORE AND AFTER TREATMENT WITH BIOLOGICAL DRUGS
    Roux, I
    Lubbe, M. S.
    Burger, J. R.
    Lamprecht, J. C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 31 - 31
  • [28] The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment
    Ceri J. Phillips
    CNS Drugs, 2004, 18 : 561 - 574
  • [29] The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment
    Phillips, CJ
    CNS DRUGS, 2004, 18 (09) : 561 - 574
  • [30] Cytokine networks in multiple sclerosis: lost in translation
    Codarri, Laura
    Fontana, Adriano
    Becher, Burkhard
    CURRENT OPINION IN NEUROLOGY, 2010, 23 (03) : 205 - 211
12345